Previous 10 | Next 10 |
I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization PR Newswire - New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization ...
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China PR Newswire SHANGHAI and GAITHERSBURG, Md. , Dec. 15, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceu...
I-Mab (NASDAQ:IMAB) announces interim data from a clinical trial of lemzoparlimab in combination with rituximab (Rituxan) in heavily treated patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), at the 63rd American Society of Hematology (ASH) Annual Meeting. Lemzoparlimab was sa...
I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021 - Positive clinical activity was observed in heavily pretreated patients who had progressed on prior Anti-CD20 therapies PR Newswir...
I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma PR Newswire SHANGHAI and GAITHERSBURG, Md. , Dec. 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clin...
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease PR Newswire SHANGHAI and GAITHERSBURG, Md. , Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceut...
Shares of I-Mab (NASDAQ:IMAB) are up 2% in premarket trading after announcing a plan to also list its shares on the The Main Board of The Stock Exchange of Hong Kong Limited. The company is headquartered in Shanghai. Last month, I-Mab and Roche (OTCQX:RHHBY) signed an agreement to c...
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited PR Newswire SHANGHAI and GAITHERSBURG, Md. , Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company ...
I-Mab (NASDAQ:IMAB) announces that the first two patients have been dosed in the U.S. phase 2 dose expansion clinical study of CD73 antibody uliledlimab (also known as TJD5) in combination with atezolizumab (Tecentriq) in patients with ovarian cancer and other selected advanced or m...
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors PR Newswire SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...